Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG–Positive NMOSD
Authors:
- Pakeeran SiriratnamPSPakeeran Siriratnam
- Saif HudaSHSaif Huda
- Anneke Van Der WaltAWAnneke Van Der Walt
- Paul G. SanfilippoPSPaul G. Sanfilippo
- Sifat SharminSSSifat Sharmin
- Yi Chao FoongYFYi Chao Foong
- Wei Z. YehWYWei Z. Yeh
- Chao ZhuCZChao Zhu
- Samia J. KhourySKSamia J. Khoury
- Tunde CsepanyTunde Csepany
- Barbara WillekensBWBarbara Willekens
- Masoud EtemadifarMEMasoud Etemadifar
- 24 December 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (12) , e209940
Abstract
In aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed to assess the prevalence of progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) in AQP4-IgG NMOSD. This was a retrospective cohort study of patients with AQP4-IgG NMOSD enrolled in the MSBase international data registry. Patients required a minimum of 3 recorded Expanded Disability Status Scale (EDSS) scores: baseline, event, and a 6-month confirmation score. Presence and absence of relapses between the baseline and event EDSS scores determined RAW and PIRA, respectively. Descriptive statistics were used to present the results. A total of 181 patients followed for a median of 4.5 years (Q1 1.7, Q3 7.8) were included. Most patients were female (88.4%), and the median age at disease onset was 38.1 years. Overall, 4 patients (2.2%) developed 5 incidences of PIRA and 13 patients developed RAW (7.2%). This multicenter study highlights that PIRA is very rare in AQP4-IgG NMOSD. Limitations of this study include the sole focus of overall EDSS to measure disability, lack of requirement for a second EDSS score to confirm baseline EDSS, and the absence of magnetic resonance imaging information for all patients.Keywords
This publication has 15 references indexed in Scilit:
- Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple SclerosisJAMA Neurology, 2023
- Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosisMultiple Sclerosis and Related Disorders, 2023
- A comprehensive review of the advances in neuromyelitis optica spectrum disorderAutoimmunity Reviews, 2023
- Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple SclerosisJAMA Neurology, 2023
- Neuromyelitis optica: Clinical course and potential prognostic indicatorsMultiple Sclerosis and Related Disorders, 2022
- Cognitive impairment in NMOSD—More questions than answersBrain and Behavior, 2020
- Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disordersScientific Reports, 2020
- Retinal ganglion cell loss in neuromyelitis optica: a longitudinal studyJournal of Neurology, Neurosurgery & Psychiatry, 2018
- Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis opticaJournal of Neuroimmunology, 2017
- Defining secondary progressive multiple sclerosisBrain, 2016